EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple‐Negative Breast Cancer

Meng Xu iD, Yingchun Zhang, Rubing Mei, Tingting Xue, Hongning Cai, Yu Zhou, Jianfang Guo

Journal of Cellular and Molecular Medicine · 2026-06 · 30 (11)

DOI: 10.1111/jcmm.71219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 01.06.2026. Verfasst von Meng Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese, Maternal and Child Health Hospital of Hubei Province, Wuhan, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Lignans, Cyclooctanes, Polycyclic Compounds. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Health Technology Project of Hubei Provincial, Natural Science Foundation of Hubei Province, General Program of China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to elucidate the mechanism of action of Schisandrin A in the intervention of triple‐negative breast cancer (TNBC). Through the application of network pharmacology and the integration of targets from multiple databases, the research identified 128 overlapping targets between Schisandrin A and TNBC. From these, 36 core targets were determined via topological analysis. Utilizing the random forest survival algorithm, four prognosis‐related core targets (GSK3B, IDO1, KDR, PKM) were identified from the METABRIC database, and the model's predictive performance was validated using the GSE58812 dataset. Pan‐cancer expression analysis confirmed the aberrant expression of these four targets across various tumours. Immune infiltration analysis suggested that GSK3B and IDO1 may influence the tumour immune microenvironment. Molecular docking studies demonstrated a high binding affinity of Schisandrin A with IDO1 and PKM. In vitro cell experiments indicated that Schisandrin A inhibited the proliferation of MDA‐MB‐231 cells in a concentration‐dependent manner, induced apoptosis and caused cell cycle arrest at the S phase. Transcriptome sequencing further revealed the transcriptional changes induced by Schisandrin A, elucidating that the cell cycle and DNA replication are the primary regulatory pathways affected. In conclusion, Schisandrin A exhibits potential anti‐triple‐negative breast cancer (TNBC) effects by modulating and regulating diverse pathways, including GSK3B and IDO1, alongside its impact on the cell cycle and immune microenvironment. This study presents novel candidate drugs and therapeutic targets for the precise treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsLignansCyclooctanesPolycyclic CompoundsNetwork PharmacologyHumansFemaleGene Expression Regulation, NeoplasticCell ProliferationMolecular Docking SimulationApoptosisMDA-MB-231 CellsCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

GSK3B/IDO1/KDR/PKMSchisandrin anetwork pharmacologyprognostic modeltriple‐negative breast cancer

Substanzen

LignansCyclooctanesPolycyclic Compoundsschizandrin A

Autor:innen und Institutionen

  • Department of Traditional Chinese, Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
  • Health Management Center, Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
  • Research and Development Center of Science and Technology, Wuhan University, Wuhan, China.

ORCID-Profile: Meng Xu

Förderung

  • Health and Health Technology Project of Hubei Provincial
  • Natural Science Foundation of Hubei Province
  • General Program of China Postdoctoral Science Foundation
  • National Famous Veteran Traditional Chinese Medicine Expert Inheritance Studio Construction Project in the Field of Maternal and Child Health

Zitieren

APA

Xu, M., Zhang, Y., Mei, R., Xue, T., Cai, H., Zhou, Y., & Guo, J. (2026). Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple‐Negative Breast Cancer. Journal of Cellular and Molecular Medicine, 30(11). https://doi.org/10.1111/jcmm.71219

Vancouver

Xu M, Zhang Y, Mei R, Xue T, Cai H, Zhou Y, et al. Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple‐Negative Breast Cancer. Journal of Cellular and Molecular Medicine. 2026;30(11). doi:10.1111/jcmm.71219

BibTeX
@article{Xu2026,
  author = {Xu, Meng and Zhang, Yingchun and Mei, Rubing and Xue, Tingting and Cai, Hongning and Zhou, Yu and Guo, Jianfang},
  title = {Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple‐Negative Breast Cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {11},
  doi = {10.1111/jcmm.71219}
}
Kostenlos starten →